Tumor immunology and immunotherapy for endometrial cancer.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY Expert opinion on investigational drugs Pub Date : 2025-02-11 DOI:10.1080/13543784.2025.2463091

Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, Noriomi Matsumura

{"title":"Tumor immunology and immunotherapy for endometrial cancer.","authors":"Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, Noriomi Matsumura","doi":"10.1080/13543784.2025.2463091","DOIUrl":null,"url":null,"abstract":"Introduction: Recent clinical trials show the efficacy of immune checkpoint inhibitors (ICIs) or a combination of ICI and poly (ADP-ribose) polymerase (PARP) inhibitors for advanced or recurrent endometrial cancer. However, the basis for such treatment effects remains unclear, hindering the advancement of personalized therapy.Areas covered: This review includes a detailed interpretation of subgroup analysis data from phase III clinical trials for endometrial cancer evaluating the efficacy of chemotherapy plus ICIs (NRG-GY018, RUBY, AtTEnd, KEYNOTE-B21) or chemotherapy plus ICI with/without olaparib (DUO-E). We focused on the relationship between obesity, the effect of PARP inhibitors, and tumor immunity in endometrial cancer, searched for relevant literature published from 2000 to 2024 in PubMed, and conducted a narrative review.Expert opinion: Chemotherapy plus ICI is appropriate for dMMR. Chemotherapy plus ICI and PARP inhibitor may be appropriate for TP53abn type or serous carcinoma because PARP inhibitor enhances the efficacy of ICI by activating the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway. Obese patients may benefit more from ICIs, and this appears to cause the variation in efficacy between regions/countries. Administration for measurable disease appears important to increase the effect of ICIs. Diet and exercise may also be important factors.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-12"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2463091","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Recent clinical trials show the efficacy of immune checkpoint inhibitors (ICIs) or a combination of ICI and poly (ADP-ribose) polymerase (PARP) inhibitors for advanced or recurrent endometrial cancer. However, the basis for such treatment effects remains unclear, hindering the advancement of personalized therapy.

Areas covered: This review includes a detailed interpretation of subgroup analysis data from phase III clinical trials for endometrial cancer evaluating the efficacy of chemotherapy plus ICIs (NRG-GY018, RUBY, AtTEnd, KEYNOTE-B21) or chemotherapy plus ICI with/without olaparib (DUO-E). We focused on the relationship between obesity, the effect of PARP inhibitors, and tumor immunity in endometrial cancer, searched for relevant literature published from 2000 to 2024 in PubMed, and conducted a narrative review.

Expert opinion: Chemotherapy plus ICI is appropriate for dMMR. Chemotherapy plus ICI and PARP inhibitor may be appropriate for TP53abn type or serous carcinoma because PARP inhibitor enhances the efficacy of ICI by activating the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway. Obese patients may benefit more from ICIs, and this appears to cause the variation in efficacy between regions/countries. Administration for measurable disease appears important to increase the effect of ICIs. Diet and exercise may also be important factors.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.